Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants
Open Access
- 12 March 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 74 (6), 701-709
- https://doi.org/10.1007/s00228-018-2435-3
Abstract
Purpose Inhaled drug delivery is an attractive route by which to deliver drugs to lungs of patients with idiopathic pulmonary fibrosis (IPF). GSK3008348 is a potent and selective small molecule being developed as the first inhaled inhibitor of the αvβ6 integrin for the treatment of IPF. The phase 1 first-time-in-human clinical trial (NCT02612051) presented here was designed to investigate the safety, tolerability and pharmacokinetic (PK) profile of single doses of GSK3008348 in healthy participants. Methods Single ascending doses of GSK3008348 were administered to three cohorts of eight healthy participants in a randomised, double-blind, placebo-controlled, 4-period crossover design. Safety, tolerability and PK were assessed after single doses of 1–3000 mcg given by nebulisation. Results A total of 29 participants were enrolled and received at least one dose of study treatment. There were no serious adverse events (AE) reported in any participant. No trends or clinically important differences were noted in the incidence or intensity of AEs or other safety assessments. Maximum plasma concentrations of GSK3008348 were generally attained within approximately 30 min after start of nebulisation, with geometric mean terminal elimination half-lives ranging from 7.95 to 10.2 h. Exposures, as measured by area under the plasma concentration-time curve (AUC), were dose proportional across all doses where estimates were possible (100–3000 mcg). Dose normalised geometric mean Cmax increased with dose up to 3000 mcg. This supra proportionality was relatively modest, with a less than 3-fold increase over the range from 30 to 3000 mcg. The reason(s) for this observation are currently not known but may be due to slower absorption at the lowest doses. All exposures were within the exposure margins set by the non-clinical toxicity studies and so this is not expected to have any impact on safety. Conclusions In summary, GSK3008348 was well tolerated at single doses up to 3000 mcg in healthy participants, and its PK profile was dose proportional at potentially clinically relevant doses (300–3000 mcg). These findings support further development of GSK3008348 as a novel inhaled treatment option for IPF.Keywords
Funding Information
- GSK
This publication has 15 references indexed in Scilit:
- Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligandBiochemical Pharmacology, 2016
- αvβ6 integrin may be a potential prognostic biomarker in interstitial lung diseaseEuropean Respiratory Journal, 2015
- Assessment of the effect of potential antifibrotic compounds on total and αVβ6 integrin-mediated TGF-β activationPharmacology Research & Perspectives, 2014
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Induction of Heart Valve Lesions by Small-Molecule ALK5 InhibitorsToxicologic Pathology, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Transforming Growth Factor-βActivation in the Lung: Focus on Fibrosis and Reactive Oxygen SpeciesAntioxidants and Redox Signaling, 2008
- Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating InflammationAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Idiopathic Pulmonary Fibrosis: Diagnosis and TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2000
- A Mechanism for Regulating Pulmonary Inflammation and Fibrosis: The Integrin αvβ6 Binds and Activates Latent TGF β1Cell, 1999